An open-label, randomised, phase I/II trial of ruCaparib combined with Nivolumab with or without Ipilimumab to augment response in homologous repair deficient patients with relapsed Ovarian, primary peritoneal and fallopian tube cancer

Trial Profile

An open-label, randomised, phase I/II trial of ruCaparib combined with Nivolumab with or without Ipilimumab to augment response in homologous repair deficient patients with relapsed Ovarian, primary peritoneal and fallopian tube cancer

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Rucaparib (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms CeNturIOn
  • Most Recent Events

    • 16 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top